Subcutaneous · GLP-1 agonist
TG103
11 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
11
Active
0
Recruiting
0
Completed
7
Sites
6
Countries
1
Endpoints
145
Composite endpoints
4
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
4
Phase 2
4
Phase 3
3
Trials by status
Completed
7
Unknown
4
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
41
Glycemic / diabetes
35
Weight & body composition
31
Cardiometabolic biomarkers
23
Other (unclassified)
12
Patient-reported / QoL
2
Renal / kidney
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
4
Postprandial glucoseGlycemic
3
HbA1c <6.5% achievementGlycemic
2
Fasting glucose, changeGlycemic
2
Body weight, absolute change (kg)Weight
2
Plasma concentration (steady state)Safety/PK
2
Immunogenicity (ADA)Safety/PK
2
Treatment-emergent AEs (any)Safety/PK
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
11 of 11